STOCK TITAN

Immunitybio Inc Stock Price, News & Analysis

IBRX Nasdaq

Welcome to our dedicated page for Immunitybio news (Ticker: IBRX), a resource for investors and traders seeking the latest updates and insights on Immunitybio stock.

ImmunityBio Inc (NASDAQ: IBRX) is a clinical-stage biotechnology leader developing immunotherapies that activate both innate and adaptive immune responses. This dedicated news hub provides investors and researchers with essential updates on clinical trial progress, regulatory milestones, and strategic partnerships.

Access real-time updates on key developments including Anktiva (IL-15 superagonist) trials, oncology treatment advancements, and innovative data management collaborations. Our curated feed consolidates earnings reports, FDA communications, and scientific publications to streamline your due diligence process.

Discover comprehensive coverage of:

- Phase 1-3 clinical trial results
- Strategic licensing agreements
- Manufacturing capacity expansions
- Peer-reviewed research publications
- Conference presentation highlights

Bookmark this page for immediate access to verified information about ImmunityBio's progress in treating cancers and infectious diseases through next-generation cell therapies and vaccine platforms.

Rhea-AI Summary

ImmunityBio has announced the initiation of Phase 3 enrollment for the SISONKE Universal Boost COVID T-Cell vaccine trial in previously vaccinated participants in South Africa. The company has also expanded its GMP manufacturing capacity for various vaccine platforms across the U.S., South Africa, and Botswana. Significant clinical developments include a planned data cutoff for bladder cancer trials in January 2022 and a BLA filing expected in Q1 2022. ImmunityBio raised $470 million in financing in 2021 to support its clinical trials and expand operations. Key milestones include progressing 13 Phase 2/3 trials and securing pivotal patents.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
clinical trial covid-19
-
Rhea-AI Summary

ImmunityBio has expanded its vaccine programs to include self-amplifying self-adjuvating RNA (SASA-RNA) and recombinant protein candidates. This comprehensive platform aims to provide broad, durable protection against SARS-CoV-2 variants. Key developments include the Phase 2 SISONKE Boost trial in South Africa and partnerships with Amyris and Baylor College to accelerate production. The next-generation vaccines are designed to be cost-effective for global distribution, particularly in low- and middle-income countries, with enhanced stability and storage requirements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
covid-19
-
Rhea-AI Summary

CytRx Corporation (OTCQB:CYTR) reported its Q3 2021 results, ending on September 30 with approximately $16.5 million in cash and a net loss of $1.7 million, an improvement from a $2.8 million loss in Q3 2020. General and administrative expenses decreased to $1.5 million from $2.2 million year-over-year. The company paid $165,000 as part of a $10 million securities purchase agreement. CytRx continues to explore strategic partnerships for clinical testing while supporting ImmunityBio's Phase 2 pancreatic cancer trial and Orphazyme's regulatory pursuits regarding arimoclomol.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
none
Rhea-AI Summary

Amyris, Inc. (Nasdaq: AMRS) has formed a 50:50 joint venture with ImmunityBio, Inc. (Nasdaq: IBRX) to commercialize a next-generation COVID-19 vaccine. The binding term sheet has been signed, with a definitive agreement expected soon. ImmunityBio will handle vaccine manufacturing post-human trials in South Africa, while Amyris provides its RNA technology and sustainable squalene. The venture aims to deliver one billion doses in 2022, targeting vaccine access in developing countries and addressing supply chain challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
partnership covid-19
-
Rhea-AI Summary

ImmunityBio, Inc. (NASDAQ: IBRX) announced that Dr. Patrick Soon-Shiong will present at the 2021 Jefferies London Healthcare Conference from November 16-18, 2021. His presentation on November 18 will focus on advancements in the company’s infectious disease and oncology programs. Attendees can access the on-demand webcast starting at 8:00 am GMT. ImmunityBio is advancing over 40 clinical trials, including their lead product Anktiva™ for bladder cancer, which has received FDA's Breakthrough Therapy designation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
conferences
-
Rhea-AI Summary

ImmunityBio announced positive results from its Phase 2/3 trial of Anktiva (N-803) combined with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer. Both cohorts met primary endpoints: 57% disease-free survival after 12 months in cohort B (papillary disease) and a 72% complete response rate in cohort A (carcinoma in situ). Importantly, the therapy had no severe adverse events. A key patent for Anktiva use in bladder cancer has been granted, extending coverage until 2035.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.69%
Tags
none
Rhea-AI Summary

CytRx Corporation highlights the early efficacy of its licensed drug aldoxorubicin in ImmunityBio's Phase 2 trial for advanced pancreatic cancer. The trial shows that 90% of evaluable patients exceeded historical survival rates, with 87% of those with extremely advanced disease also surpassing these rates. Mature data is expected in Q1 2022, and ImmunityBio is expanding enrollment due to positive early results. CytRx has potential milestone payments of up to $343 million from ImmunityBio for aldoxorubicin.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.27%
Tags
-
Rhea-AI Summary

ImmunityBio has completed enrollment of 50 participants in Cohort C of its QUILT 88 trial, focusing on advanced metastatic pancreatic cancer. The early results show that 90% of evaluable patients surpassed the two-month historical survival rate with standard chemotherapy. Among the most advanced patients, 87% exceeded these rates. The company plans to increase enrollment due to the positive early data and aims to discuss approval pathways with the FDA in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
-
Rhea-AI Summary

ImmunityBio, a clinical-stage immunotherapy company, has announced the initiation of the Lung Cancer Master Protocol (Lung-MAP) trial, to evaluate its IL-15 receptor superagonist complex, N-803 (Anktiva), combined with Merck's pembrolizumab (Keytruda) for patients with non-small cell lung cancer (NSCLC) who have failed previous treatments. The study will target 478 patients and will be conducted at over 700 sites in the U.S. This landmark study aims to enhance treatment options for NSCLC patients without targetable mutations, providing a potential chemotherapy-free alternative with fewer side effects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) reported promising results from its ongoing QUILT 3.032 bladder cancer trial, revealing that 72% of 81 patients achieved a complete response to the combination of intravesical BCG and N-803 (Anktiva). The median duration of this response was 19.9 months, with 85% of patients avoiding cystectomy as of May 2021. Moreover, there were no reported treatment-related serious adverse events. The data was presented on September 10 at the American Urological Association’s Annual Meeting, highlighting the drug's potential to redefine treatment for BCG-unresponsive patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags

FAQ

What is the current stock price of Immunitybio (IBRX)?

The current stock price of Immunitybio (IBRX) is $2.81 as of July 11, 2025.

What is the market cap of Immunitybio (IBRX)?

The market cap of Immunitybio (IBRX) is approximately 2.4B.
Immunitybio Inc

Nasdaq:IBRX

IBRX Rankings

IBRX Stock Data

2.40B
228.41M
62.9%
9.88%
7.14%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN DIEGO